SCHEMBL29575643

SCHEMBL29575643

CC(C)(C)OC(=O)N1CCn2c(-c3ccc(C=O)cc3)cnc2C1

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.50
P2RX7 Q99572 8/20 0.44
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
NR1H2 P55055 1/20 0.42
GPR119 Q8TDV5 4/20 0.40
POLB P06746 1/20 0.39
CKS1B P61024 2/20 0.39
SKP1 P63208 2/20 0.39
SKP2 Q13309 2/20 0.39
EGLN2 Q96KS0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28734981 0.83 P2RX7 (0.53) PDK2P2RX7HDAC4HDAC1HDAC6
SCHEMBL27240288 0.80 NR1H2 (0.45) PDK2NR1H2GPR119POLBCKS1B
SCHEMBL28886725 0.80 PDK2 (0.47) PDK2P2RX7NR1H2GPR119
SCHEMBL30191401 0.80 P2RX7 (0.45) PDK2P2RX7HDAC4HDAC1HDAC6
SCHEMBL15519766 0.79 CFTR (0.48) PDK2P2RX7HDAC4HDAC1HDAC6
SCHEMBL25275872 0.78 CFTR (0.47) PDK2P2RX7HDAC4HDAC1HDAC6
SCHEMBL30457735 0.78 CFTR (0.47) PDK2P2RX7HDAC4HDAC1HDAC6
SCHEMBL10095054 0.77 PDK2 (0.48) PDK2P2RX7NR1H2GPR119POLB
SCHEMBL16836088 0.76 MTOR (0.47) PDK2P2RX7HDAC4HDAC1HDAC6
SCHEMBL17790245 0.76 P2RX7 (0.48) PDK2P2RX7NR1H2GPR119POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114456173-B Condensed ring group substituted cyclohexanediimide derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2023-09-19 CN disclosed
CN-114456173-A Fused ring group substituted cycloheximide derivatives, preparation method thereof and application thereof in medicines 江苏恒瑞医药股份有限公司 2022-05-10 CN disclosed